Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
The state of retina at ASRS 2025 with Charles C. Wykoff, MD, PhD, and Kevin Quinn
(Image credit: AdobeStock/vetrana) The annual scientific meeting of the American Society of Retina Specialists (ASRS) was held in Long Beach, California from July 30 through August 2, 2025. At this event, researchers and experts in the retina field shared data…
EyeCool Therapeutics appoints Vance Thompson, MD, to board of directors
EyeCool Therapeutics has appointed Vance Thompson, MD, founder of Vance Thompson Vision and immediate past president of the American Society of Cataract and Refractive Surgery (ASCRS), to the company’s board of directors. Thompson has personally performed more than 100,000 vision…
Vicky Demas on the importance of simplifying retinal screenings and incorporating AI
Vicky Demas, PhD, CEO of identifeye HEALTH, spoke to Ophthalmology Times about the company’s recent FDA registration and the it’s innovative retinal imaging technology. The company formally registered with the FDA, enabling them to market their device in the United…
Neurotech Pharmaceuticals appoints Peter J. McDonnell, MD, to Board of Directors
Photo of Peter J. McDonnell, MD, provided by Neurotech and used with permission Neurotech Pharmaceuticals, Inc., has appointed had Peter J. McDonnell, MD, to the Board of Directors. McDonnell, along with being a long-time member of the Ophthalmology Times Editorial…
EMA grants Orphan designations to MCO-010, FDA grants RMAT in Stargardt disease
(Image credit: AdobeStock/Pete) The European Medicines Agency (EMA) granted Orphan designations to MCO-010 (sonpiretigene isteparvovec) across 5 categories of retinal dystrophies. The US Food and Drug Administration (FDA) also granted RMAT designation for MCO-010 in Stargardt disease (SD). The EMA…
FDA Approves Revolutionary Eye Drops to Treat Near Vision Loss Without Glasses – Vocal
FDA Approves Revolutionary Eye Drops to Treat Near Vision Loss Without Glasses Vocal Source: Author: | Date: 2025-09-01 14:00:00 Source: Author: | Date: 2025-09-01 14:00:00
New insights show “later is better” for some LHON interventions
(Image Credit: AdobeStock/Brian Jackson) Neuro-ophthalmologist Alfredo Sadun, MD, PhD, has helped uncover surprising results from gene therapy research for Leber hereditary optic neuropathy (LHON), revealing effects far beyond the initially treated eye. LHON is a rare genetic disorder that causes…
TME Pharma’s Strategic Restructuring and Capital Efficiency: A Pathway to Value Realization in Oncology and Ophthalmology – AInvest
TME Pharma’s Strategic Restructuring and Capital Efficiency: A Pathway to Value Realization in Oncology and Ophthalmology AInvest Source: Author: | Date: 2025-09-01 09:30:00 Source: Author: | Date: 2025-09-01 09:30:00
An Interactive Corneal Sensitivity Testing Workshop
Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; and John Hovanesian, MD, FACS; discuss the importance of comprehensive…
FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Outlook Therapeutics’ biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD). The recent CRL included only 1 deficiency, for…